Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Standard Biotools (LAB) over the last 16 years, with Q3 2025 value amounting to $8.8 million.

  • Standard Biotools' Change in Accured Expenses rose 9738888.89% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.5 million, marking a year-over-year increase of 38415.36%. This contributed to the annual value of -$4.2 million for FY2024, which is 16766.94% down from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Change in Accured Expenses is $8.8 million, which was up 9738888.89% from $9.2 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Change in Accured Expenses ranged from a high of $9.2 million in Q2 2025 and a low of -$7.8 million during Q1 2025
  • Over the past 5 years, Standard Biotools' median Change in Accured Expenses value was -$195000.0 (recorded in 2022), while the average stood at -$237684.2.
  • As far as peak fluctuations go, Standard Biotools' Change in Accured Expenses tumbled by 237350.43% in 2021, and later soared by 9738888.89% in 2025.
  • Over the past 5 years, Standard Biotools' Change in Accured Expenses (Quarter) stood at -$2.8 million in 2021, then skyrocketed by 92.98% to -$195000.0 in 2022, then surged by 476.92% to $735000.0 in 2023, then crashed by 66.12% to $249000.0 in 2024, then surged by 3423.69% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $9.2 million for Q2 2025, and -$7.8 million during Q1 2025.